Tumor-Infiltrating PD-1(hi)CD8(+)-T-Cell Signature as an Effective Biomarker for Immune Checkpoint Inhibitor Therapy Response Across Multiple Cancers

BACKGROUND: Stratification of patients who could benefit from immune checkpoint inhibitor (ICI) therapy is of much importance. PD-1(hi)CD8(+) T cells represent a newly identified and effective biomarker for ICI therapy response biomarker in lung cancer. Accurately quantifying these T cells using com...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Zhenyu, Deng, Yulan, Cheng, Jiahan, Wei, Shiyou, Luo, Hao, Liu, Lunxu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8479164/
https://www.ncbi.nlm.nih.gov/pubmed/34604032
http://dx.doi.org/10.3389/fonc.2021.695006

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8479164/
https://www.ncbi.nlm.nih.gov/pubmed/34604032
http://dx.doi.org/10.3389/fonc.2021.695006

Ejemplares similares